WO2023211073A1 - Composition de biomarqueur pour prédire la susceptibilité d'un patient atteint d'un cancer à un anticorps anti-igsf1, et méthode l'utilisant - Google Patents

Composition de biomarqueur pour prédire la susceptibilité d'un patient atteint d'un cancer à un anticorps anti-igsf1, et méthode l'utilisant Download PDF

Info

Publication number
WO2023211073A1
WO2023211073A1 PCT/KR2023/005499 KR2023005499W WO2023211073A1 WO 2023211073 A1 WO2023211073 A1 WO 2023211073A1 KR 2023005499 W KR2023005499 W KR 2023005499W WO 2023211073 A1 WO2023211073 A1 WO 2023211073A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
igsf1
protein
antibody
gene encoding
Prior art date
Application number
PCT/KR2023/005499
Other languages
English (en)
Korean (ko)
Inventor
김성락
박윤선
진솔
배승건
김다은
이여진
최연승
Original Assignee
웰마커바이오 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 웰마커바이오 주식회사 filed Critical 웰마커바이오 주식회사
Publication of WO2023211073A1 publication Critical patent/WO2023211073A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the present invention provides a biomarker composition for predicting the susceptibility of a cancer patient to an anti-IGSF1 antibody and a method for providing the information necessary to predict the susceptibility of a cancer patient to an anti-IGSF1 antibody using the same.
  • Cancer is a major disease that ranks first in mortality in modern society, and despite much research, there is no technological treatment to date. Worldwide, more than 100 million cancer patients occur every year, and the World Health Organization (WHO) considers cancer to be one of the main causes of death.
  • WHO World Health Organization
  • the responsiveness of a living body when an anticancer drug is administered in anticancer therapy largely depends on the sensitivity of the targeted cancer cells to a specific drug.
  • the sensitivity of these cancer cells to drugs is greatly different for each cancer cell, and this difference in sensitivity is due to quantitative or qualitative differences in the target molecules of the drug or factors related thereto, or the acquisition of drug resistance, etc.
  • the effectiveness of the drug can be determined at an early stage, the treatment regimen can be established, and new treatments can be selected. This is possible and is very beneficial.
  • cancer cells are isolated from cancer tissue obtained by biological tissue fragments, etc. according to a conventional method and then treated with a drug, and whether the cancer cells are sensitive to the drug is measured based on the above-mentioned changes. It is very useful clinically because it is possible to predict in advance whether treatment by .
  • Republic of Korea Patent Publication No. 10-2021-0122185 discloses that an antibody against IGSF1 can be used as a pharmaceutical composition for cancer prevention or treatment.
  • no method has been disclosed at all to predict the sensitivity of cancer patients to antibodies against IGSF1.
  • the present inventors studied to develop a method to predict the sensitivity of cancer patients to antibodies against IGSF1, and as a result, it was found that the expression patterns of IGSF1 and PD-L1 in cancer cells or tissues of cancer patients show an opposite correlation. By confirming this, the present invention was completed.
  • one aspect of the present invention is a biomarker composition for predicting the susceptibility of cancer patients to anti-IGSF1 antibodies, comprising an agent capable of measuring the expression level of PD-L1 protein or the gene encoding it. provides.
  • Another aspect of the present invention provides a kit for predicting susceptibility of cancer patients to anti-IGSF1 antibodies, comprising the biomarker composition.
  • Another aspect of the present invention provides information necessary for predicting the susceptibility of a cancer patient to an anti-IGSF1 antibody, comprising measuring the expression level of the PD-L1 protein or the gene encoding it in a biological sample obtained from the individual. Provides a method to provide.
  • Another aspect of the present invention provides a method of selecting cancer patients suitable for treatment with an anti-IGSF1 antibody, comprising selecting an individual with a low expression level of the PD-L1 protein or the gene encoding it.
  • the susceptibility of individual cancer patients to anti-IGSF1 antibody can be determined by measuring the expression level of PD-L1 protein or the gene encoding it. Since accurate predictions can be made before treatment, it is possible to select an anticancer drug with high therapeutic effect and prevent side effects from unnecessary use of anticancer drugs.
  • Figure 1a shows the results of Western blot (top) and RT-PCR (bottom) to confirm changes in the expression pattern of PD-L1 due to IGSF1 overexpression in NCI-H292, a non-small cell lung cancer cell line. ⁇ -actin and GAPDH are controls for each experiment.
  • Figure 1b shows the results of Western blotting to confirm changes in the expression pattern of PD-L1 when IGSF1 was knocked down in a cell line with stable IGSF1 overexpression.
  • Figure 2a shows the results of Western blotting to confirm changes in the expression pattern of PD-L1 when IGSF1 was knocked down in three lung cancer cell lines (NCI-H520, NCI-H1435, NCI-H1944) expressing IGSF1.
  • Figure 2b shows the results of Western blotting to confirm changes in the expression pattern of PD-L1 when IGSF1 was overexpressed in two lung cancer cell lines (Calu-1, NCI-H2228) that do not express IGSF1.
  • Figure 3 shows a Western blot to confirm changes in the expression pattern of PD-L1 when co-transfected with increasing amounts of the IGSF1 expression vector while maintaining a fixed amount of the PD-L1 expression vector in 293T, a human embryonic kidney cell line. This is the result of the performance.
  • Figure 4 is a photograph (top) of a tissue showing an inverse correlation between the expression patterns of IGSF1 and PD-L1 by performing immunohistochemical staining, and the IGSF1 expression levels are categorized as 0(-), 1(+), and 2( ++), 3(+++), and PD-L1 is a graph created by calculating the TPS value (bottom).
  • Figure 5a shows the results of confirming the binding between ATF3, a downstream signal of IGSF1, and PD-L1 through chromatin immunoprecipitation when IGSF1 was knocked down in a cell line stably overexpressing IGSF1.
  • Figure 5b shows the results of RT-PCR (top) and Western blot (bottom) to confirm changes in the expression patterns of ATF3 and PD-L1 due to inhibition of IGSF1 expression in lung cancer cell lines NCI-H838 and NCI-H358. GAPDH and ⁇ -actin are controls for each experiment.
  • Figure 5c shows the results of RT-PCR (top) and Western blot (bottom) to confirm changes in the expression patterns of ATF3 and PD-L1 due to IGSF1 overexpression in NCI-H292 cells, a lung cancer cell line. GAPDH and ⁇ -actin are controls for each experiment.
  • Figure 6 is a diagram showing the results of identifying IGSF1 protein using TMT labeling LC/MS in lung cancer cell lines with different PD-L1 expression levels.
  • One aspect of the present invention provides a biomarker composition for predicting susceptibility of cancer patients to anti-IGSF1 antibodies, including an agent capable of measuring the expression level of PD-L1 protein or the gene encoding it.
  • Immunoglobulin superfamily member 1 is a plasma membrane glycoprotein encoded by the IGSF1 gene found on the X chromosome of humans and other mammalian species. Although the function of IGSF1 in normal cells is not well known, IGSF1 mutations are known to cause diseases such as IGSF1 deficiency syndrome or central hypothyroidism.
  • PD-L1 refers to a protein present on the surface of cancer cells or hematopoietic cells.
  • PD-L1 and PD-L2 on the surface of cancer cells are PD-L1, a protein on the surface of T cells. When combined with 1, T cells cannot attack cancer cells.
  • the term “susceptibility” refers to whether an anti-IGSF1 antibody exhibits a therapeutic effect for an individual cancer patient. It is known that even types of therapeutic agents recognized as effective for cancer treatment may or may not be effective depending on the individual patient. Whether or not a treatment is effective for an individual cancer patient can be referred to as sensitivity to the treatment.
  • biomarker may also be used as a companion diagnosis marker and refers to a substance that can predict in advance a patient's responsiveness to a specific drug treatment in a biological sample.
  • Polypeptides or nucleic acids e.g., mRNA, etc.
  • lipids e.g., glycolipids, glycoproteins, or sugars (e.g., monosaccharides, disaccharides, oligosaccharides, etc.) that are shown to be increased or decreased in biological samples taken from certain cancer patients. It may include organic biomolecules, etc.
  • cancer refers to the aggressive nature of cells dividing and proliferating in defiance of normal growth limits, the invasive nature of infiltrating surrounding tissues, and the ability to spread to other parts of the body. It refers to a general term for diseases caused by cells with metastatic characteristics, and is used in the same sense as malignant tumor.
  • treatment of cancer means inhibiting or preventing the growth of cancer cells or tissues, which reduces cancer growth and cancer metastasis compared to no treatment or treatment, and reduces resistance to anticancer drugs. This concept also includes making the treatment more effective.
  • the cancer metastasis refers to the process by which tumor (cancer) cells spread to distant parts of the body, and "resistance to anticancer drugs” or “anticancer drug resistance” refers to the initial stage of treatment when treating cancer patients using anticancer drugs. This means that there is no treatment effect or that the cancer treatment effect is initially effective but the cancer treatment effect is lost during the continuous treatment process.
  • the expression level of the PD-L1 protein or the gene encoding the same in the responding patient group showing a therapeutic effect against the anti-IGSF1 antibody compared to the non-responsive cancer patient group showing no therapeutic effect against the anti-IGSF1 antibody may decrease.
  • the expression level of PD-L1 protein or the gene encoding it is increased in the non-responsive cancer patient group that does not show a therapeutic effect to the anti-IGSF1 antibody compared to the responsive cancer patient group that shows a therapeutic effect to the anti-IGSF1 antibody. can do.
  • the cancer may be one in which the IGSF1 protein or the gene encoding it is overexpressed.
  • the cancer consists of stomach cancer, liver cancer, lung cancer, colon cancer, breast cancer, prostate cancer, ovarian cancer, pancreas cancer, cervical cancer, thyroid cancer, laryngeal cancer, acute myeloid leukemia, brain tumor, neuroblastoma, retinoblastoma, head and neck cancer, salivary gland cancer, and lymphoma. It may be any one selected from the group, but is not limited thereto, and may be applicable to any tumor tissue in which the IGSF1 protein or the gene encoding it is present.
  • Measuring the expression level of the PD-L1 protein is a process of confirming the presence and expression level of the protein in a biological sample isolated from a cancer patient in order to predict the cancer patient's sensitivity to the anti-IGSF1 antibody, The amount of protein is confirmed using a molecule that specifically binds to the protein.
  • Agents that can measure the expression level of the protein include monoclonal antibodies, polyclonal antibodies, chimeric antibodies, ligands, PNA (peptide nucleic acid), and aptamers ( It may be one or more selected from the group consisting of an aptamer and a nanoparticle, but is not limited thereto.
  • Analysis methods for this include western blotting, ELISA (enzyme linked immunosorbent assay), radioimmunoassay (RIA), radioimmunodiffusion, ouchterlony immunodiffusion, and rocket ( rocket) immunoelectrophoresis, immunoprecipitation assay, immunohistochemical analysis, complement fixation assay, FACS (fluorescence activated cell sorter), protein chip, two-dimensional electrophoresis Electrophoretic analysis, protein mass spectrometry, liquid chromatography-mass spectrometry (LC-MS), LC-MS/MS (liquid chromatography-mass spectrometry/mass spectrometry), MALDI-TOF (matrix desorption/ionization time) of flight mass spectrometry) analysis and SELDI-TOF (surface enhanced laser desorption/ionization time of flight mass spectrometry) analysis, etc., but are not limited thereto.
  • LC-MS liquid chromatography-mass spectrometry
  • LC-MS/MS
  • Measurement of the expression level of the gene encoding the protein determines the presence or absence of the gene encoding the protein in biological samples isolated from cancer patients and the expression level of the gene in order to predict the susceptibility of the cancer patient to the anti-IGSF1 antibody. In the process of confirming, the amount of the gene is confirmed using a molecule that specifically binds to the gene.
  • An agent capable of measuring the expression level of a gene encoding the protein may be at least one selected from the group consisting of a primer pair, a probe, and an antisense nucleotide that specifically binds to the gene. However, it is not limited to this.
  • RT-PCR reverse transcriptase-polymerase chain reaction
  • RPA RNase protection assay
  • Northern include, but are not limited to, northern blotting and DNA chips.
  • the expression patterns of PD-L1 and IGSF1 show a reverse correlation.
  • Another aspect of the present invention provides a kit for predicting the sensitivity of cancer patients to anti-IGSF1 antibodies, including the biomarker composition.
  • the kit can predict sensitivity to the anti-IGSF1 antibody using biological samples isolated from cancer patients. Specifically, the kit can predict sensitivity to the anti-IGSF1 antibody using tumor tissue collected from a cancer patient.
  • the kit may include tools and reagents commonly used in immunological analysis, as well as agents for measuring the expression level of the protein or gene.
  • the tool or reagent may include, but is not limited to, a suitable carrier, a labeling substance capable of generating a detectable signal, a chromophore, a solubilizer, a detergent, a buffer, and a stabilizer.
  • a labeling substance capable of generating a detectable signal
  • a chromophore capable of generating a detectable signal
  • a solubilizer a detergent
  • a buffer a buffer
  • stabilizer a stabilizer.
  • Carriers include soluble carriers and insoluble carriers.
  • soluble carriers include physiologically acceptable buffers known in the art, such as PBS, and examples of insoluble carriers include polystyrene, polyethylene, polypropylene, polyester, It may be polyacrylonitrile, fluororesin, cross-linked dextran, polysaccharide, polymers such as magnetic fine particles plated with metal on latex, other paper, glass, metal, agarose, and combinations thereof.
  • the biomarker composition is as described above.
  • Another aspect of the present invention provides information necessary for predicting the susceptibility of a cancer patient to an anti-IGSF1 antibody, comprising measuring the expression level of the PD-L1 protein or the gene encoding it in a biological sample obtained from the individual. Provides a method to provide.
  • the method may additionally include the step of predicting sensitivity to an anticancer agent containing an anti-IGSF1 antibody when the expression level of the PD-L1 protein or the gene encoding it is lower than the reference value. Specifically, when the expression level of the PD-L1 protein or the gene encoding it is lower than the reference value, the expression level of the IGSF1 protein or the gene encoding it can be predicted to be high.
  • the term “reference value” refers to amplification/non-amplification of a gene; Alternatively, it refers to a value that serves as a standard for dividing over- or under-expression of mRNA or protein.
  • the reference value may be, for example, the average mRNA/protein expression level of an individual before treatment with a specific drug, or the average mRNA/protein expression level of a normal individual, but is not limited thereto.
  • the reference value may be determined according to the distribution of the average mRNA/protein expression level of a specific patient group, but is not limited thereto.
  • the mRNA expression level or protein expression level is measured by measuring the average mRNA expression level or protein expression level from each individual sample using a method for measuring gene, mRNA, or protein levels commonly used in the technical field of the present invention. , top 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% 10%, 11%, 12%, 13%, 14%, 15% of the distribution of measurements.
  • biological sample refers to any sample obtained from an individual in which the expression level of the PD-L1 protein or the gene encoding it can be measured.
  • the biological sample may be, but is not limited to, blood, plasma, serum, urine, saliva, sputum, cerebrospinal fluid, cell culture fluid, tissue extract, or tumor tissue.
  • the biological sample may be tumor tissue collected from an individual for biopsy.
  • the biological sample can be prepared by processing by methods commonly used in the art.
  • the cancer may be one in which the IGSF1 protein or the gene encoding it is overexpressed.
  • the cancer consists of stomach cancer, liver cancer, lung cancer, colon cancer, breast cancer, prostate cancer, ovarian cancer, pancreas cancer, cervical cancer, thyroid cancer, laryngeal cancer, acute myeloid leukemia, brain tumor, neuroblastoma, retinoblastoma, head and neck cancer, salivary gland cancer, and lymphoma. It may be any one selected from the group, but is not limited thereto, and may be applicable to any tumor tissue in which the IGSF1 protein or the gene encoding it is present.
  • PD-L1 and IGSF1 are as described above.
  • Another aspect of the present invention provides a method of selecting cancer patients suitable for treatment with an anti-IGSF1 antibody, comprising selecting an individual with a low expression level of the PD-L1 protein or the gene encoding it.
  • the anti-IGSF1 antibody, PD-L1 protein expression level, cancer, etc. are as described above.
  • Redundant content is omitted in consideration of the complexity of the present specification, and terms not otherwise defined in this specification have meanings commonly used in the technical field to which the present invention pertains.
  • Example 1 Analysis of expression patterns of IGSF1 and PD-L1 in non-small cell lung cancer cell lines
  • Example 1.1 Analysis of PD-L1 expression pattern according to IGSF1 overexpression
  • the non-small cell lung cancer cell line NCI-H292 (Korean Cell Line Bank, KCLB) was genetically engineered to overexpress IGSF1 (NCI-H292 IGSF1 O/E), and as a negative control, an empty vector (pCMV6 entry) was added to NCI-H292. , Origene PS100001) was used (NCI-H292 MOCK).
  • the IGSF1 expression vector pCMV6 entry IGSF1, Origene, RC209621 was transfected into NCI-H292 cells using jetPRIME reagent, and treated with 800 ⁇ g/ml of G418 starting 2 days later. After treatment with G418, the transfected cells were selected for 1 month to obtain a single clone (clone F) IGSF1 overexpressing stable cell line.
  • target category cat.# Manufacturer IGSF1 Mouse IgG (primary antibody) sc-393786 SantaCruz Biotechnology, Inc.
  • PD-L1 Rabbit IgG (primary antibody) ab205921 Abcam ⁇ -actin Mouse IgG (primary antibody) sc-47778 SantaCruz Biotechnology, Inc.
  • RNA was extracted and quantified with Trizol, and then 2,000 ng of RNA was prepared. Subsequently, cDNA was synthesized using the AccuPower ® CycleScript RT PreMix kit using 100 pmole 1 ⁇ l of oligo dt primer. PCR was performed on 2 ⁇ l of the synthesized cDNA in an AB Veriti 96-Well Thermal Cycler using the AccuPower ® PCR PreMix kit for 28 cycles. After completing PCR, 5 ⁇ l of each sample was loaded onto a 1% agarose gel, electrophoresed at 150 V for 35 minutes, and changes in mRNA expression levels were confirmed through UV irradiation in Gel-Doc. The results are shown in Figure 1a. Primer information used in PCR is as listed in Table 2 below.
  • Example 1.2 Analysis of PD-L1 expression pattern according to decreased IGSF1 expression
  • Example 2 Analysis of expression patterns of IGSF1 and PD-L1 in various lung cancer cell lines
  • Example 2.1 Analysis of PD-L1 expression pattern according to inhibition of IGSF1 expression
  • NCI-H520 (ATCC), NCI-H1435 (KCLB), and NCI-H1944 (ATCC) cells were inoculated at 5x10 5 cells/dish in a 60 mm 2 culture dish and cultured for 24 hours, followed by Scrambled shRNA and IGSF1. 200 pmol of each shRNA was transfected using JetPrime reagent. Scrambled (sc) shRNA is a negative control for IGSF1 shRNA, and IGSF1 shRNA is for knocking down IGSF1. After culturing the transfected cells for 48 hours and collecting them, the cells were lysed using RIPA buffer. Western blot was performed using the cell lysed sample in the same manner as described in Example 1.1, and the results are shown in Figure 2a.
  • Example 2.2 Analysis of PD-L1 expression pattern according to induction of IGSF1 expression
  • Lung cancer cell lines Calu-1 (KCLB) and NCI-H2228 (ATCC) cells were inoculated into a 60 mm 2 culture dish at 5x10 5 cells/dish and cultured for 24 hours, followed by empty vector and HA-tagged IGSF1 expression. 2 ⁇ g of each vector was transfected using JetPrime reagent. After culturing the transfected cells for 48 hours and collecting them, the cells were lysed using RIPA buffer and Western blot was performed. Specifically, cell lysis samples were reacted with Bradford solution and quantified at a wavelength of 595 nm. 15 ⁇ g of cell lysis sample was loaded onto an 8% SDS-gel and subjected to SDS-PAGE, and then the sample present in the gel was transferred to a PVDF membrane at 100V for 120 minutes.
  • the primary antibodies anti-IGSF1 antibody, anti-HA antibody, anti-PD-L1 antibody, and anti- ⁇ -actin antibody
  • the secondary antibody HRP (horseradish peroxidase)-conjugated mouse antibody
  • HRP horseradish peroxidase
  • the signal was amplified using an enhanced chemiluminescence (ECL) solution, sensitized to film, developed, and the change in protein expression level was measured.
  • ECL enhanced chemiluminescence
  • 293T (ATCC) cells a human embryonic kidney cell line, were inoculated at 5x10 5 cells/dish in a 60 mm 2 culture dish and cultured for 24 hours.
  • the amount of PD-L1 expression vector was fixed at 0.5 ⁇ g, and the amount of IGSF1 expression vector was increased to 0 ⁇ g, 0.5 ⁇ g, 1.0 ⁇ g, 1.5 ⁇ g, and 2.0 ⁇ g and co-transfected using JetPrime reagent. After culturing the transfected cells for 48 hours and collecting them, the cells were lysed using RIPA buffer. Western blot was performed using the cell lysed sample in the same manner as described in Example 1.1, and the results are shown in Figure 3.
  • Example 4 In non-small cell lung cancer patient tissue Expression pattern analysis of IGSF1 and PD-L1
  • immunohistochemistry was performed. Specifically, tissue sections from 84 human non-small cell lung cancer patients were deparaffinized and rehydrated. For heat-induced epitope recovery, the cells were soaked in target recovery buffer, heated in a microwave oven for 15 minutes, and left in target recovery buffer for an additional 30 minutes.
  • TBS-T Tris-buffered saline-0.05% Tween 20
  • IGSF1 is subdivided into 0(-), 1(+)(negative/low), 2(++), and 3(+++)(positive/high), and PD-L1 is classified into tumor proportion score (TPS). ) values were calculated and subdivided into ⁇ 1, 1 ⁇ 4.9, 5 ⁇ 49 (negative/low), and ⁇ 50 (positive/high).
  • TPS tumor proportion score
  • the expression patterns of IGSF1 and PD-L1 in the tissues of non-small cell lung cancer patients show an inverse correlation (bottom), and the tissues with IGSF1 (positive/high) and PD-L1 (negative/low) It was confirmed that 34.5%, IGSF1 (negative/low), and PD-L1 (positive/high) were 3.6%.
  • Example 5 Analysis of PD-L1 gene expression regulation by IGSF1 in various lung cancer cell lines
  • Example 5.1 Analysis of the interaction between ATF3, a downstream signal of IGSF1, and PD-L1
  • the ATF3 binding site (binding site) was identified on the PD-L1 promoter through PD-L1 promoter chip assay depending on whether IGSF1 was expressed or not. ) and conducted an experiment. The results were confirmed through chromatin immunoprecipitation.
  • lung cancer cell lines NCI-H292 mock and NCI-H292 IGSF1 O/E cells were cultured by adding 37% formaldehyde to a concentration of 1% for 15 minutes at room temperature. During the culture, 740 mL glycine (1 M) was added and incubated at room temperature for 5 minutes, and then the cells were harvested. Cross-linked cells were then melted in SDS lysis buffer and sonicated to obtain DNA fragments. Chromatin was immunoprecipitated with ATF3 antibody or IgG antibody and agarose at 4°C. Chromatin, antibody, and agarose complex were eluted by adding sodium chloride during the washing process, and reverse histone-DNA crosslinks were performed at 65°C.
  • Polymerase chain reaction was performed using 1 ⁇ L of immunoprecipitated DNA using primers specific to the PD-L1 promoter. Information on the antibodies used in immunoprecipitation is as shown in Table 4 below, and information on primers used in the polymerase chain reaction is as shown in Table 5 below.
  • Example 5.2 Analysis of expression patterns of ATF3 and PD-L1 according to inhibition of IGSF1 expression
  • RT-PCR Reverse transcription-polymerase chain reaction
  • Western blot was used to analyze changes in the expression patterns of ATF3 and PD-L1 according to IGSF1 K/D (knock down) in lung cancer cell lines NCI-838 and NCI-H358 cells. blot) was performed.
  • NCI-838 and NCI-H358 cells were treated with Trizol, RNA was extracted and quantified. Afterwards, cDNA was synthesized using the AccuPower® CycleScript RT PreMix kit using 1 ⁇ L of 100 pmole of oligo dt primer for 2000 ng of RNA. PCR was performed on 2 ⁇ L of the synthesized cDNA in an AB Veriti 96-Well Thermal Cycler using the AccuPower® PCR PreMix kit for 28 cycles. After completing PCR, 5 ⁇ L of each sample was loaded onto a 1% agarose gel and electrophoresed at 150 V for 35 minutes. Afterwards, changes in mRNA expression levels were confirmed through UV irradiation in Gel-Doc.
  • Example 5.3 Analysis of expression patterns of ATF3 and PD-L1 according to IGSF1 overexpression
  • IGSF1 protein was identified using TMT labeling LC/MS in lung cancer cell lines with different levels of PD-L1 expression.
  • membrane proteins from human non-small cell lung cancer cell lines were extracted using the Subcellular Protein Fractionation Kit (Thermo Scientific, 78840). Quantity of extracted protein was measured using Bradford assay (Bio-Rad, 5000001). 50 ⁇ g of each protein was reacted with 10 mM Tris(2-carboxyethyl)phosphine (TCEP) at 55°C for 1 hour, 18.75 mM iodoacetamide for 30 minutes at room temperature, and then precipitated with acetone overnight at -20°C. .
  • TCEP Tris(2-carboxyethyl)phosphine
  • the protein pellet precipitated with acetone was dissolved in 50 mM triethylammonium bicarbonate (TEAB), 2.5 ⁇ g of trypsin (1:40) per 100 ⁇ g of protein was added, and the protein was cleaved overnight at 37°C to peptide.
  • TMT-labeling was performed using the TMTsixplex TM labeling reagent set (Thermo Scientific, 90066), and the protocol was performed according to the manufacturer's specifications.
  • Mass spectrometry and protein identification was performed using an LTQ-Orbitrap Hybrid FT-ETD mass spectrometer (Thermo Scientific).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne : une composition de biomarqueur pour prédire la susceptibilité d'un patient atteint d'un cancer à un anticorps anti-IGSF1 ; et une méthode pour fournir des informations requises pour prédire la susceptibilité d'un patient atteint d'un cancer à un anticorps anti-IGSF1 à l'aide de celle-ci. Par conséquent, la susceptibilité individuelle d'un patient atteint d'un cancer à un anticorps anti-IGSF1 peut être prédite avec précision avant le traitement par l'intermédiaire d'une méthode de mesure du niveau d'expression de la protéine PD-L1 ou d'un gène codant pour celle-ci, et ainsi un médicament anticancéreux ayant un effet thérapeutique élevé peut être sélectionné, et des effets secondaires provoqués par l'utilisation de médicaments anticancéreux inutiles peuvent être empêchés.
PCT/KR2023/005499 2022-04-25 2023-04-21 Composition de biomarqueur pour prédire la susceptibilité d'un patient atteint d'un cancer à un anticorps anti-igsf1, et méthode l'utilisant WO2023211073A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20220050770 2022-04-25
KR10-2022-0050770 2022-04-25

Publications (1)

Publication Number Publication Date
WO2023211073A1 true WO2023211073A1 (fr) 2023-11-02

Family

ID=88519327

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/005499 WO2023211073A1 (fr) 2022-04-25 2023-04-21 Composition de biomarqueur pour prédire la susceptibilité d'un patient atteint d'un cancer à un anticorps anti-igsf1, et méthode l'utilisant

Country Status (2)

Country Link
KR (1) KR20230151916A (fr)
WO (1) WO2023211073A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101811731B1 (ko) * 2014-07-29 2018-01-25 재단법인 아산사회복지재단 Met 저해제에 대한 감수성 예측용 신규한 바이오 마커 및 이의 용도
US20190128892A1 (en) * 2016-04-14 2019-05-02 Creatv Microtech, Inc. Methods of using pd-l1 expression in treatment decisions for cancer therapy
WO2021201571A1 (fr) * 2020-03-31 2021-10-07 웰마커바이오 주식회사 Composition pharmaceutique pour la prévention ou le traitement du cancer contenant un anticorps dirigé contre igsf1 en tant que principe actif, et méthode de traitement du cancer l'utilisant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101811731B1 (ko) * 2014-07-29 2018-01-25 재단법인 아산사회복지재단 Met 저해제에 대한 감수성 예측용 신규한 바이오 마커 및 이의 용도
US20190128892A1 (en) * 2016-04-14 2019-05-02 Creatv Microtech, Inc. Methods of using pd-l1 expression in treatment decisions for cancer therapy
WO2021201571A1 (fr) * 2020-03-31 2021-10-07 웰마커바이오 주식회사 Composition pharmaceutique pour la prévention ou le traitement du cancer contenant un anticorps dirigé contre igsf1 en tant que principe actif, et méthode de traitement du cancer l'utilisant

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHUNGMAN LEE: "GSK Invests about 1 Trillion KRW to Develop Next-generation Immune Anti-cancer Drugs in Earnest. ", HEALTH KOREA NEWS, 5 April 2023 (2023-04-05), XP093103220, Retrieved from the Internet <URL: https://www.hkn24.com/news/articleView.html?idxno=332412> [retrieved on 20231120] *
SEUNGDEOK LEE: "Well Marker Bio-Samsung Bio Immuno-oncology CDMO Contract Signed. ", MEDICAL NEWSPAPER, 15 March 2021 (2021-03-15), XP093103219, Retrieved from the Internet <URL:http://www.bosa.co.kr/news/articleView.html?idxno=2146179> [retrieved on 20231120] *
WELLMARKER BIO: "Wellmarker Bio Announces Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab)", CISION PR NEWSWIRE, 7 February 2023 (2023-02-07), XP093103218, Retrieved from the Internet <URL:https://www.prnewswire.co.uk/news-releases/wellmarker-bio-announces-clinical-trial-collaboration-with-msd-to-evaluate-wm-a1-3389-in-combination-with-keytruda-pembrolizumab-301740567.html> [retrieved on 20231120] *
YAOYAO GUAN; YINGHAO WANG; ADHEESH BHANDARI; ERJIE XIA; OUCHEN WANG: "IGSF1: A novel oncogene regulates the thyroid cancer progression", CELL BIOCHEMISTRY AND FUNCTION., BUTTERWORTH, GUILDFORD., GB, vol. 37, no. 7, 25 July 2019 (2019-07-25), GB , pages 516 - 524, XP071523442, ISSN: 0263-6484, DOI: 10.1002/cbf.3426 *

Also Published As

Publication number Publication date
KR20230151916A (ko) 2023-11-02

Similar Documents

Publication Publication Date Title
Necela et al. Folate receptor-α (FOLR1) expression and function in triple negative tumors
Kanamoto et al. Functional proteomics of transforming growth factor‐β1‐stimulated Mv1Lu epithelial cells: Rad51 as a target of TGFβ1‐dependent regulation of DNA repair
Prabhu et al. Critical role of phosphorylation of serine 165 of YBX1 on the activation of NF-κB in colon cancer
Uchino et al. Clinical implication and prognostic significance of the tumor suppressor TSLC1 gene detected in adenocarcinoma of the lung
WO2009113814A2 (fr) Marqueur protéique utilisé pour le diagnostic précoce du cancer du foie
Zhang et al. MiR-216a-5p inhibits tumorigenesis in pancreatic cancer by targeting TPT1/mTORC1 and is mediated by LINC01133
Zhu et al. Trabid inhibits hepatocellular carcinoma growth and metastasis by cleaving RNF8-induced K63 ubiquitination of Twist1
Zhang et al. Phosphorylation of Ser 78 of Hsp27 correlated with HER-2/neu status and lymph node positivity in breast cancer
Lin et al. Targeting anthrax toxin receptor 2 ameliorates endometriosis progression
Zhou et al. MiR-650 represses high-risk non-metastatic colorectal cancer progression via inhibition of AKT2/GSK3β/E-cadherin pathway
WO2006036175A2 (fr) Proteines wnt et detection et traitement du cancer
Guerrero et al. C3G-mediated suppression of oncogene-induced focus formation in fibroblasts involves inhibition of ERK activation, cyclin A expression and alterations of anchorage-independent growth
Chen et al. Identification of nasopharyngeal carcinoma metastasis-related biomarkers by iTRAQ combined with 2D-LC-MS/MS
WO2016152352A1 (fr) Biomarqueur spécifique du mélanome et son utilisation
Sun et al. Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer
St. Clair et al. Fyn‐dependent phosphorylation of PlexinA1 and PlexinA2 at conserved tyrosines is essential for zebrafish eye development
Song et al. Elevated eukaryotic elongation factor 2 expression is involved in proliferation and invasion of lung squamous cell carcinoma
Chang et al. DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib Resistance in Clear Cell Renal Cell Carcinoma
Li et al. BRD7 inhibits enhancer activity and expression of BIRC2 to suppress tumor growth and metastasis in nasopharyngeal carcinoma
Arai et al. Expression of DNA damage response proteins in gastric cancer: Comprehensive protein profiling and histological analysis
Men et al. RUFY3 predicts poor prognosis and promotes metastasis through epithelial-mesenchymal transition in lung adenocarcinoma
WO2005107803A2 (fr) Procédés de détermination du pronostic et du traitement de sujets souffrant d&#39;un cancer du poumon
WO2023211073A1 (fr) Composition de biomarqueur pour prédire la susceptibilité d&#39;un patient atteint d&#39;un cancer à un anticorps anti-igsf1, et méthode l&#39;utilisant
Lin et al. miR-1247-3p targets STAT5A to inhibit lung adenocarcinoma cell migration and chemotherapy resistance
EP1287020A2 (fr) Diagnostic du cancer et tests de criblage d&#39;agents anticancereux

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23796720

Country of ref document: EP

Kind code of ref document: A1